The Renal Biomarkers Market, estimated at USD 1,728.0 Mn in 2025, is expected to exhibit a CAGR of 8.2% and reach USD 3,000.1 Mn by 2032.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
The key market players are focused on adopting growth strategies such as collaborations and acquisitions, which will drive the global renal biomarkers market. For instance, in September 2025, Baxter International Inc., a multinational healthcare company, announced a distribution agreement with bioMérieux, a multinational biotechnology company, for the NEPHROCLEARTM CCL14 diagnostic test. The NEPHROCLEARTM CCL14 test is currently in development for use in assessing the risk of developing persistent severe acute kidney injury (AKI). As part of the agreement, Baxter will be bioMérieux's exclusive distributor of the NEPHROCLEARTM CCL14 test in Europe and the U.S. following regulatory approval and launch in both markets. Baxter and bioMérieux will share in-country commercialization, while bioMérieux will retain control over the regulatory approval process. Incorporating new diagnostic products into Baxter's Acute Therapies portfolio advances the company’s efforts to support overall patient management by providing solutions that enable efficiencies in critical care.
Global Renal Biomarkers Market Market– Impact of Coronavirus (COVID-19) Pandemic
The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. This virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.
COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems with regard to the transportation of drugs from one place to another.
COVID-19 had a positive impact on the global renal biomarkers market. For instance, in August 2025, according to an article published in the journal Nature reviews of Nephrology, the article estimated approximately 20% of patients of U.S. on dialysis died within 1 month of SARS-CoV-2 infection — substantially higher than the risk of death associated with other infections or many cardiovascular events. Excess mortality among patients on maintenance dialysis was nearly 30% higher relative to preceding 5-year trends during the initial height of the pandemic in the U.S. and the U.K.
Global Renal Biomarkers Market: Key Developments
On April 28, 2025, The Fiscal Year 2025 (FY23) Defense Appropriations Act provides funding for the Kidney Cancer Research Program (KCRP) to support research of exceptional scientific merit in the area of kidney cancer. The managing agent for the anticipated funding opportunities is the CDMRP (Congressionally Directed Medical Research Programs) at the U.S. Army Medical Research and Development Command (USAMRDC). The KCRP is providing the information in this pre-announcement to allow investigators time to plan and develop ideas for submission to the anticipated FY23 funding opportunities.
In November 2025, Boditech Med, Inc., a pharmaceutical company that provides diagnostic solutions entered into a license agreement with SphingoTec GmbH, a biotechnology company, for the kidney function biomarker Proenkephalin A 119-159 (penKid). Under the terms of this agreement, Boditech Med has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma Point of Care platforms. SphingoTec has a monopoly on the penKid, a unique biomarker for real-time assessment of kidney function.
On January 5, 2025, Bruker Corporation, manufacturer of scientific instruments for molecular and materials research, as well as for industrial and applied analysis, announced the acquisition of ACQUIFER Imaging GmbH, a pioneer in big-data management solutions, for bioimaging and high-content microscopy. This acquisition adds high-performance on-premise processing, secure storage and networking technology that complements Bruker’s advanced fluorescence microscopy imaging products, such as light-sheet and super-resolution microscopy products, which generate high information content.